Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil Desai

Showing results (21-30 of 72) with videos related to

Pageof 8
Sort By:
Neoplasia (New York, N.Y.)|January 30, 2009
Aberrant promoter methylation of SPARC in ovarian cancerMatthew J Socha, Neveen Said, Yanshan Dai, et al.
Circulation|September 5, 2002
Sustained reduction of in-stent neointimal growth with the use of a novel systemic nanoparticle paclitaxelFrank D Kolodgie, Michael John, Charanjit Khurana, et al.
International Journal of Radiation Oncology, Biology, Physics|April 18, 2026
Metastasis-directed Therapy in Oligometastatic Castration-resistant Prostate Cancer: From Chasing the Last Metastasis to Changing the Game?Thomas Zilli, Nicholas G Zaorsky, Priyamvada Maitre, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2005
Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol)Alex Sparreboom, Charity D Scripture, Vuong Trieu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2006
Influence of formulation vehicle on metronomic taxane chemotherapy: albumin-bound versus cremophor EL-based paclitaxelSylvia S W Ng, Alex Sparreboom, Yuval Shaked, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2005
Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignanciesDavid W Nyman, Kimberley J Campbell, Evan Hersh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2005
Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancerNuhad K Ibrahim, Brian Samuels, Ray Page, et al.
Artificial Intelligence in Medicine|November 12, 2021
PSA-Net: Deep learning-based physician style-aware segmentation network for postoperative prostate cancer clinical target volumesAnjali Balagopal, Howard Morgan, Michael Dohopolski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 3, 2008
Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxelErin R Gardner, William L Dahut, Charity D Scripture, et al.
Biomedical Physics & Engineering Express|January 19, 2024
Simulation and pre-planning omitted radiotherapy (SPORT): a feasibility study for prostate cancerTingliang Zhuang, David Parsons, Neil Desai, et al.
Pageof 8

Showing results (21-30 of 72) with videos related to

Sort By:
Pageof 8
Neoplasia (New York, N.Y.)|January 30, 2009
Aberrant promoter methylation of SPARC in ovarian cancerMatthew J Socha, Neveen Said, Yanshan Dai, et al.
Circulation|September 5, 2002
Sustained reduction of in-stent neointimal growth with the use of a novel systemic nanoparticle paclitaxelFrank D Kolodgie, Michael John, Charanjit Khurana, et al.
International Journal of Radiation Oncology, Biology, Physics|April 18, 2026
Metastasis-directed Therapy in Oligometastatic Castration-resistant Prostate Cancer: From Chasing the Last Metastasis to Changing the Game?Thomas Zilli, Nicholas G Zaorsky, Priyamvada Maitre, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2005
Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol)Alex Sparreboom, Charity D Scripture, Vuong Trieu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2006
Influence of formulation vehicle on metronomic taxane chemotherapy: albumin-bound versus cremophor EL-based paclitaxelSylvia S W Ng, Alex Sparreboom, Yuval Shaked, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2005
Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignanciesDavid W Nyman, Kimberley J Campbell, Evan Hersh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2005
Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancerNuhad K Ibrahim, Brian Samuels, Ray Page, et al.
Artificial Intelligence in Medicine|November 12, 2021
PSA-Net: Deep learning-based physician style-aware segmentation network for postoperative prostate cancer clinical target volumesAnjali Balagopal, Howard Morgan, Michael Dohopolski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 3, 2008
Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxelErin R Gardner, William L Dahut, Charity D Scripture, et al.
Biomedical Physics & Engineering Express|January 19, 2024
Simulation and pre-planning omitted radiotherapy (SPORT): a feasibility study for prostate cancerTingliang Zhuang, David Parsons, Neil Desai, et al.
Pageof 8